Jobs and Employment Information about jobs, labors, experiencies and news Related Articles
Medicines Azempik d Munjaro were developed to treat adult patients with uncontrolled type 2 diabetes, but they have gained popularity due to their weight loss effect and are being taken by more people worldwide.
+ Want to know more about innovation? Join the Época NEGÓCIOS group on WhatsApp
So the pharmaceutical companies responsible for them, Eli Lilly and Novo Nordisk, respectively, are now testing whether the drugs are also safe for children who need to lose weight.
- Ozempic and other animal venom inspired remedies
- After Ozempic comes the rebound: in the study, participants lost up to 24% of their weight
According to Bloomberg News, the former announced plans to offer it to boys and girls as young as six, and last week began recruiting children as young as 12 for clinical trials.
“We are certainly committed to innovation in this space that will reach all affected populations,” an Eli Lilly spokesperson said in the report.
In Novo Nordisk’s case, Saxenda, which is an older and less potent version of Ozempic, and Wegovy are already in clinical trials for children at least six years old.
According to the New York Post, in the second quarter of 2023, the companies recorded the largest year-over-year revenue growth based on drug sales.
Analysts polled by FactSet expect Novo Nordisk to report sales of US$3.32 billion (about R$16.7 billion) from Ozempic and US$1.07 billion (R$5.4 billion) from Wegovy for this period.
Ozempic’s second-quarter revenue reached US$3.2 billion (R$16.1 billion), up R$1.1 billion (R$5.5 billion) from the April-June 2022 period Eli Lilly’s Mounjaro, in turn, recorded US$980 million (R$4.9 billion). ) in sales at the same time, a 72% increase over the first quarter.
